14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT)

Perimenopause, Menopause & Hormone Replacement Therapy (HRT)

The menopausal transition represents a profound neuroendocrine and multisystem physiological evolution in women. Advanced practice nursing in adult-gerontology requires expertise in interpreting menstrual irregularities, managing debilitating vasomotor and genitourinary symptoms, assessing cardiovascular and skeletal risk profiles, and navigating the complexities of systemic versus local menopausal hormone therapy (MHT).

---

1. Reproductive Aging Taxonomy & Endocrinology

The Stages of Reproductive Aging Workshop (STRAW + 10) defines the staging criteria from peak reproductive life through late postmenopause.

+---------------------------------------------------------------------------------------------------+
|                             STRAW + 10 REPRODUCTIVE AGING SPECTRUM                                |
|                                                                                                   |
|   [STAGE -2: EARLY MENOPAUSAL TRANSITION (PERIMENOPAUSE)]                                         |
|   - Menstrual Cycles: Variable cycle length; persistent difference of ≥7 days in length of        |
|     consecutive cycles.                                                                           |
|   - Endocrine: Declining inhibin B; fluctuating estradiol; variable/elevated early follicular FSH.|
|                                     |                                                             |
|                                     v                                                             |
|   [STAGE -1: LATE MENOPAUSAL TRANSITION (PERIMENOPAUSE)]                                          |
|   - Menstrual Cycles: Marked cycle irregularity with interval of amenorrhea ≥60 days.             |
|   - Symptoms: Vasomotor symptoms (VMS) peak in prevalence and severity.                           |
|   - Endocrine: Elevated FSH (>25 mIU/mL); erratic estradiol surges and troughs.                   |
|                                     |                                                             |
|                                     v                                                             |
|   [STAGE 0: FINAL MENSTRUAL PERIOD (FMP) / NATURAL MENOPAUSE]                                     |
|   - Diagnostic Hallmark: 12 CONSECUTIVE MONTHS of spontaneous amenorrhea in a woman ≥45 years    |
|     without other pathological or physiological cause. (Median age in US: 51.4 years).            |
|                                     |                                                             |
|                                     v                                                             |
|   [STAGE +1 to +2: EARLY & LATE POSTMENOPAUSE]                                                    |
|   - Endocrine: Depleted ovarian follicular reserve -> Permanent loss of negative feedback from    |
|     estradiol and inhibin B -> Persistently elevated FSH (typically >40 mIU/mL) and low estradiol.|
|   - Clinical: Progressive urogenital atrophy (Genitourinary Syndrome of Menopause) and bone loss. |
+---------------------------------------------------------------------------------------------------+

Clinical Definitions:

• Premature Ovarian Insufficiency (POI): Loss of normal ovarian function occurring before age 40, characterized by amenorrhea $\ge 4\text{ months}$, hypoestrogenism, and elevated gonadotropins (two serum FSH levels $>40\text{ IU/L}$ obtained $\ge 4\text{ weeks}$ apart). Requires physiological MHT until at least the median age of natural menopause (~51 years) to preserve bone mineral density and reduce premature cardiovascular mortality.
• Early Menopause: Menopause occurring between ages 40 and 45.
• Diagnostic Lab Testing Rule: In women aged $>45$ years presenting with classic perimenopausal or menopausal symptoms (irregular menses, vasomotor flushes, vaginal dryness), routine FSH and estradiol testing is NOT recommended or required. In this cohort, FSH levels fluctuate unpredictably day-to-day and do not alter clinical management.

---

2. Pathophysiology of Clinical Manifestations

+---------------------------------------------------------------------------------------------------+
|                         NEUROENDOCRINE PATHOPHYSIOLOGY OF VASOMOTOR FLUSHES                       |
|                                                                                                   |
|   [DECLINING OVARIAN ESTROGEN]                                                                    |
|                                     |                                                             |
|                                     v                                                             |
|   [LOSS OF NEGATIVE FEEDBACK ON ARCUATE NUCLEUS OF HYPOTHALAMUS]                                  |
|   - Hypertrophy and upregulation of KNDy neurons (expressing Kisspeptin, Neurokinin B, Dynorphin) |
|   - Excessive release of Neurokinin B (NKB)                                                       |
|                                     |                                                             |
|                                     v                                                             |
|   [ACTIVATION OF NEUROKININ-3 (NK3) RECEPTORS ON THERMOREGULATORY CENTER]                         |
|   - Narrowing of the hypothalamic thermoregulatory set-point window                               |
|   - Minor core body temperature elevations trigger exaggerated heat-dissipation responses:        |
|     * Profuse cutaneous vasodilation (flushing of face/chest)                                     |
|     * Intense diaphoresis and tachycardia followed by chills / shivering                          |
+---------------------------------------------------------------------------------------------------+

Genitourinary Syndrome of Menopause (GSM)

GSM encompasses anatomical, histological, and functional changes in the labia, clitoris, vagina, urethra, and bladder driven by estrogen depletion:

• Pathophysiology: Loss of estrogen leads to thinning and desquamation of the stratified squamous epithelium of the vaginal mucosa, loss of vaginal rugae, diminished submucosal capillary vascularity, and loss of intracellular glycogen.
• Microbiome Shift: Absence of glycogen causes depletion of protective Lactobacillus species. Vaginal $\text{pH}$ rises from an acidic baseline ($3.8\text{--}4.5$) to alkaline ($>5.0\text{--}6.5$), predisposing to colonization by enteric pathogens (E. coli, Enterococcus).
• Clinical Presentation: Vulvovaginal dryness, severe burning, pruritus, dyspareunia (painful intercourse), introital stenosis, postcoital spotting, urinary urgency, dysuria, and recurrent postmenopausal urinary tract infections (UTIs).

---

3. Menopausal Hormone Therapy (MHT / HRT)

The "Timing Hypothesis" / "Window of Opportunity"

Data from randomized trials (including extended follow-ups of the Women's Health Initiative [WHI]) and consensus guidelines from The Menopause Society (formerly NAMS 2022/2023) confirm that the safety and efficacy of MHT depend fundamentally on age and time since menopause onset:

+---------------------------------------------------------------------------------------------------+
|                         THE MENOPAUSE SOCIETY: TIMING HYPOTHESIS                                  |
|                                                                                                   |
|   [FAVORABLE BENEFIT-RISK PROFILE: INITIATION IN WINDOW OF OPPORTUNITY]                           |
|   - Criteria: Age <60 years OR within 10 years of menopause onset.                                |
|   - Clinical Benefits:                                                                            |
|     * Statistically significant reduction in all-cause mortality (RR ~0.70 - 0.80)                |
|     * Significant reduction in Coronary Heart Disease (CHD) and myocardial infarction             |
|     * Robust reduction in osteoporotic hip and vertebral fractures                                |
|     * Complete resolution of moderate-to-severe vasomotor symptoms and sleep disturbance          |
|                                                                                                   |
|   [UNFAVORABLE BENEFIT-RISK PROFILE: LATE INITIATION]                                             |
|   - Criteria: Age ≥60 years OR >10 - 20 years past menopause onset.                               |
|   - Clinical Risks: Increased incidence of stroke, coronary events, VTE, and dementia.            |
+---------------------------------------------------------------------------------------------------+

The Mandatory Structural Rule of Systemic MHT

+---------------------------------------------------------------------------------------------------+
|                             SYSTEMIC MHT REGIMEN SELECTION RULES                                  |
|                                                                                                   |
|   1. INTACT UTERUS (No Prior Hysterectomy):                                                       |
|      - MUST PRESCRIBE COMBINED ESTROGEN + PROGESTOGEN (or Estrogen + Bazedoxifene SERM).          |
|      - Mechanism: Unopposed systemic estrogen stimulates continuous endometrial mitotic activity,  |
|        increasing the risk of endometrial hyperplasia and adenocarcinoma 8- to 10-fold!           |
|      - Progestogen options:                                                                       |
|        * Micronized Progesterone (Prometrium): 100 mg daily continuous OR 200 mg cyclic 12-14 d/mo|
|        * Medroxyprogesterone Acetate (MPA): 2.5 mg daily continuous OR 5 mg cyclic 12-14 d/mo    |
|        * Levonorgestrel 52 mg IUD (off-label endometrial protection for MHT)                      |
|                                                                                                   |
|   2. ABSENT UTERUS (Prior Surgical Hysterectomy):                                                 |
|      - PRESCRIBE ESTROGEN ALONE (ET - Estrogen Therapy).                                          |
|      - Clinical Rationale: No endometrial tissue exists; progestogen is NOT required. In the WHI,  |
|        estrogen-alone therapy showed no increase in breast cancer and a trend toward reduction.   |
+---------------------------------------------------------------------------------------------------+

Routes of Administration: Transdermal vs. Oral Estrogen

+---------------------------------------------------------------------------------------------------+
|                         TRANSDERMAL VS. ORAL 17-BETA ESTRADIOL                                    |
|                                                                                                   |
|   TRANSDERMAL ESTRADIOL (Patch, Gel, Spray)       ORAL ESTRADIOL (Pills)                          |
|   - Bypasses hepatic first-pass metabolism.       - Subject to hepatic first-pass metabolism.     |
|   - NO induction of hepatic coagulation factors   - Induces synthesis of Factors II, VII, VIII,  |
|     (Factors VII, VIII, prothrombin).               X, and fibrinogen; lowers Antithrombin III.   |
|   - Negligible/no increase in VTE or stroke risk. - Increases relative risk of VTE and Stroke.    |
|   - Neutral effect on serum triglycerides.        - Increases serum triglycerides significantly.  |
|   - PREFERRED INITIAL ROUTE FOR:                  - Avoid in women with hypertriglyceridemia,     |
|     * Hypertension, Obesity (BMI ≥30 kg/m²)         uncontrolled hypertension, or VTE risks.      |
|     * Hypertriglyceridemia, Diabetes mellitus                                                     |
|     * Elevated baseline thromboembolic risk                                                       |
|     * Gallbladder disease / cholelithiasis                                                        |
+---------------------------------------------------------------------------------------------------+

Local (Vaginal) Estrogen Therapy for GSM

• Formulations: Vaginal estradiol cream (0.5–1 g 2–3 times/week), low-dose estradiol vaginal tablets (Vagifem 10 mcg twice weekly), or estradiol vaginal ring (Estring 7.5 mcg/24 hr replaced every 90 days).
• Pharmacokinetics & Safety: Minimal systemic absorption. Re-acidifies vaginal $\text{pH}$, restores glycogen and Lactobacillus, thickens epithelium, and resolves dyspareunia and recurrent UTIs.
• Critical Board Rule: Local low-dose vaginal estrogen DOES NOT REQUIRE co-administration of a progestogen, even in women with an intact uterus.

Absolute Contraindications to Systemic MHT

• Current, past, or suspected Breast Cancer
• Known or suspected Estrogen-dependent Neoplasia (e.g., Endometrial Adenocarcinoma)
• Active or past history of Venous Thromboembolism (DVT or PE)
• Active or past history of Arterial Thromboembolism (Ischemic Stroke, TIA, Myocardial Infarction)
• Active severe Liver Disease / Hepatic Impairment (elevated baseline transaminases)
• Unexplained, undiagnosed Abnormal Uterine Bleeding (AUB) (must rule out malignancy first!)
• Known or suspected pregnancy; Porphyria cutanea tarda

---

4. Non-Hormonal Pharmacotherapy for Vasomotor Symptoms

For patients with absolute contraindications to MHT (e.g., breast cancer survivors) or those who choose not to take hormones, evidence-based non-hormonal agents are available:

+---------------------------------------------------------------------------------------------------+
|                         NON-HORMONAL PHARMACOTHERAPY FOR HOT FLASHES                              |
|                                                                                                   |
|   1. NEUROKININ-3 (NK3) RECEPTOR ANTAGONIST:                                                      |
|      - Fezolinetant (Veozah): 45 mg orally once daily with or without food.                       |
|      - MOA: Selectively blocks NKB binding on KNDy neurons in the hypothalamus, directly restoring|
|        thermoregulatory set-point balance. First non-hormonal agent targeting root pathophysiology|
|      - Hepatic Safety Monitoring: MUST obtain baseline ALT, AST, total and direct bilirubin.     |
|        Repeat transaminases at 3 months, 6 months, and 9 months of therapy.                       |
|      - Contraindications: Severe renal impairment (eGFR <30 mL/min), cirrhosis, or concomitant   |
|        use of moderate/strong CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine).               |
|                                                                                                   |
|   2. SELECTIVE SEROTONIN / NOREPINEPHRINE REUPTAKE INHIBITORS (SSRIs / SNRIs):                    |
|      - Paroxetine Mesylate (Brisdelle): 7.5 mg orally at bedtime. (Only FDA-approved SSRI for VMS)|
|        * CRITICAL BOARD DRUG INTERACTION: NEVER prescribe paroxetine or fluoxetine to women taking|
|          TAMOXIFEN! Paroxetine/fluoxetine are potent CYP2D6 inhibitors that block conversion of   |
|          tamoxifen into its active metabolite (endoxifen), causing breast cancer recurrence.      |
|      - Venlafaxine (Effexor XR): 37.5 to 75 mg orally daily. (First-line choice for women on      |
|        tamoxifen due to negligible CYP2D6 inhibition; monitor blood pressure).                   |
|      - Desvenlafaxine (Pristiq): 100 mg daily; Escitalopram: 10 - 20 mg daily.                    |
|                                                                                                   |
|   3. GABAPENTINOIDS:                                                                              |
|      - Gabapentin (Neurontin): 300 to 900 mg orally at bedtime. Excellent for nocturnal hot       |
|        flashes accompanied by significant sleep architecture disruption. (Sedation side effect).  |
|                                                                                                   |
|   4. CENTRALLY ACTING ALPHA-2 AGONISTS:                                                           |
|      - Clonidine: 0.1 mg daily oral or weekly transdermal patch. (Side effects: dry mouth,        |
|        sedation, hypotension, rebound hypertension upon abrupt withdrawal).                       |
+---------------------------------------------------------------------------------------------------+

---

5. Postmenopausal Osteoporosis Screening, FRAX & Management

Estrogen deficiency accelerates bone turnover, decoupling osteoclastic bone resorption from osteoblastic formation.

A. Screening Guidelines (USPSTF Grade B)

• Universal Screening: All women aged $\ge 65\text{ years}$ via Dual-Energy X-ray Absorptiometry (DEXA) of the lumbar spine and femoral neck/total hip.
• Targeted Screening in Younger Postmenopausal Women (<65 years): Screen if 10-year major osteoporotic fracture risk on the FRAX tool is $\ge 8.4%$ (equivalent to a 65-year-old white female without additional risk factors) OR if clinical risk factors are present (current smoking, low body weight $<127\text{ lbs}$ [BMI $<21\text{ kg/m}^2$], parental hip fracture, glucocorticoid therapy $\ge 5\text{ mg}$ prednisone equivalent daily $\ge 3\text{ months}$, rheumatoid arthritis, heavy alcohol use).

B. World Health Organization (WHO) T-Score Diagnostic Criteria

• Normal: T-score $\ge -1.0$ standard deviations (SD)
• Osteopenia (Low Bone Mass): T-score between $-1.0$ and $-2.5$ SD
• Osteoporosis:
  1. T-score $\le -2.5$ SD at lumbar spine, total hip, or femoral neck; OR
  2. History of a Fragility (Low-Trauma) Fracture of the hip or spine, regardless of T-score; OR
  3. Osteopenia (T-score $-1.0$ to $-2.5$) plus elevated FRAX 10-year probability of hip fracture $\ge 3.0%$ or major osteoporotic fracture (MOF) $\ge 20%$.

C. Pharmacotherapy for Postmenopausal Osteoporosis

• First-Line Antiresorptive Therapy (Oral Bisphosphonates):
  • Alendronate (Fosamax) 70 mg weekly or Risedronate (Actonel) 35 mg weekly.
  • Administration Protocol: Take first thing in the morning with a full 8-ounce glass of plain water, at least 30–60 minutes before any food, beverage, or other medications. Must remain upright (sitting or standing) for $\ge 30\text{ minutes}$ to prevent pill-induced erosive esophagitis.
  • Contraindications: Esophageal stricture/achalasia, inability to sit upright for 30 minutes, severe renal impairment (eGFR $<35\text{ mL/min}$).
  • Long-Term Adverse Events: Atypical subtrochanteric femur fractures and Osteonecrosis of the Jaw (ONJ). Consider a "drug holiday" after 3–5 years of treatment in low-to-moderate risk patients.
• IV Bisphosphonate: Zoledronic Acid (Reclast) 5 mg IV infusion once yearly (eGFR must be $\ge 35\text{ mL/min}$; ensure adequate hydration).
• RANKL Inhibitor: Denosumab (Prolia) 60 mg SubQ every 6 months. Safe in renal impairment. Critical Pearl: Discontinuation causes rapid rebound bone loss and severe risk of multiple vertebral fractures; must transition immediately to a bisphosphonate if stopped.
• SERM: Raloxifene (Evista) 60 mg daily. Estrogen agonist in bone (prevents vertebral fractures); estrogen antagonist in breast (reduces invasive ER-positive breast cancer risk) and uterus. Does not cause endometrial hyperplasia. Side effect: Worsens hot flashes and increases VTE risk.
• Baseline Supplementation: Calcium $1,200\text{ mg/day}$ (dietary + supplement) and Vitamin D3 $800\text{--}2,000\text{ IU/day}$.

---

6. Board-Yield Summary & Clinical Pearls

+---------------------------------------------------------------------------------------------------+
|                                 ANCC AGPCNP CLINICAL EXAM PEARLS                                  |
|                                                                                                   |
|   - Any postmenopausal woman with an intact uterus who receives systemic estrogen MUST also       |
|     receive a progestogen to prevent endometrial cancer. (Estrogen alone = 8-10x cancer risk!).  |
|                                                                                                   |
|   - In women with prior hysterectomy, prescribe Estrogen ALONE. Progestogens are not indicated.   |
|                                                                                                   |
|   - Local vaginal estrogen for GSM does NOT require a progestogen, carries minimal systemic       |
|     absorption, and is first-line for postmenopausal dyspareunia and recurrent UTIs.             |
|                                                                                                   |
|   - Paroxetine and Fluoxetine are strictly CONTRAINDICATED in patients taking TAMOXIFEN due to    |
|     potent CYP2D6 inhibition; use VENLAFAXINE (SNRI) instead.                                     |
|                                                                                                   |
|   - Fezolinetant (Veozah) is an NK3 receptor antagonist for hot flashes that requires baseline,   |
|     3-month, 6-month, and 9-month hepatic transaminase monitoring.                                |
|                                                                                                   |
|   - In a healthy 52-year-old female with classic hot flashes and amenorrhea, do NOT order FSH/LH; |
|     diagnose menopause clinically.                                                                |
+---------------------------------------------------------------------------------------------------+